Tonix Pharmaceuticals Holding Corp.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. Other Information
Rule 10b5-1 Trading Arrangements and Non-Rule 10b5-1 Trading Arrangements
On June 20, 2025, Bradley Saenger, our Chief Financial Officer, adopted a Rule 10b5-1 plan providing for the sale of up to 51,584 shares of the Company’s common stock. Pursuant to this plan, Mr. Saenger may sell shares of common stock beginning on February 25, 2026, subject to the terms of the agreement, and the plan terminates on February 28, 2028. The trading arrangement is intended to satisfy the affirmative defense of rule 10b5-1(c).
On June 18, 2025, Jessica Morris, our Chief Operating Officer, adopted a Rule 10b5-1 plan providing for the sale of up to 19,520 shares of the Company’s common stock. Pursuant to this plan, Ms. Morris may sell shares of common stock beginning on February 26, 2026, subject to the terms of the agreement, and the plan terminates on December 31, 2026. The trading arrangement is intended to satisfy the affirmative defense of rule 10b5-1(c).
No other directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarter ended June 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.